We are thrilled to announce a new partnership between the Foundation for Peripheral Neuropathy (FPN) and GlaxoSmithKline (GSK) as a 2024 Research Impact Partner. This collaboration, with GSK’s generous support, marks a significant step forward in our mission to improve the lives of those living with peripheral neuropathy.
Expanding our reach
Since our establishment in 2007, FPN has been dedicated to serving as the premier resource for information on peripheral neuropathy, funding crucial research, and raising public awareness about this debilitating condition. Our partnership with GSK will enable us to further these efforts by enhancing our distribution of research-based information, providing active research opportunities for patients and caregivers, and advancing scientific research for new treatments and cures.
This partnership is essential for enabling FPN to continue its vital work and help millions of peripheral neuropathy patients lead better lives. We look forward to providing even more patients, families, and caregivers with the information, resources, and hope they need.
Thank you, GSK, for joining us in this important mission.
For more information about corporate partnerships like these, please reach out to April Hubert, Director of Development and External Affairs, at [email protected]